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Animal Work
Variations in pupillary size were observed in experi-
ments on ten tracheotomised rabbits: in four animals the
cannula was clamped abruptly and completely until the
rabbit died; in two animals the cannula was compressed
partially, gradually increasing obstruction until the
respiration ceased; and in four animals several short-
lasting total compressions were alternated with full
release of the clamp, until after a certain time total
compression was maintained until cessation of breathing
efforts. The results are seen in table ill.
TABLE III-PUPIL SIZES IN RABBITS BEFORE AND AFTER CIRCULATORY
ARREST
In no animal was dilatation of the pupils recorded at
any time before death. On the contrary, pupillary size
decreased after complete obstruction, this being very
pronounced during the last 30 seconds of straining and
vigorous respiratory effort. In experiments with inter-
mittent compression or gradually augmented com-
pression of the canula the diameter of the pupils remained
unchanged for as long as 54 minutes and always until just
after death.
In those animals who had intermittent compression of
the breathing tube, no change in the pupillary size was
recorded during periods of l/z-2 minutes of complete
obstruction, nor after full release of the clamp. When
total obstruction exceeded 2 minutes pupillary diameter
rapidly decreased. If at that moment the clamp was
released, the rabbits survived and the pupils quickly
dilated to a diameter up to some 2 mm. larger than that
before the experiment, but after this they regained
their original size. When the clamp was not released
while the pupils were constricted, which lasted some
30 seconds, death supervened, this being accompanied
by increase in the pupillary diameter. After death the
pupils again started to get smaller after a few minutes.
Discussion
Patients in respiratory failure who had clinical signs of
severe hypoxia and a P a02 as low as 34 mm. Hg, did not
display any increase in pupillary diameter. An increase
in pupillary size cannot, apparently, be used as a reliable
sign of anoxia, even when the anoxia is severe.
Under thiopentone anxsthesia a patient’s pupils vary
with the depth of anaesthesia, but, as in unanxsthetised
cases, the size was not influenced by anoxia, even when
this was severe.
In rabbits, ansesthetised and not anaesthetised, pro-
longed and severe respiratory distress did not result in
pupillary dilatation. On the contrary, pupils contracted
during the last 30 seconds before death. Circulatory
arrest was followed by an immediate increase of pupillary
diameter, independent of whether the animal was
ansesthetised or not.
These clinical observations and experimental data do
not support the common concept that anoxia causes a
dilatation of the pupils. Estimation of pupillary size should
be omitted from a simple clinical evaluation of anoxia.
The findings do not support the suggestion (Macintosh
and Bannister 1945) that pupillary dilatation during
anaesthesia overdosage is due to anoxia. In our series,
neither anoxsemia nor brain-tissue anoxia seem to have
caused dilatation, judging from those cases with a very
low Pa02 where the brain tissue must have suffered
hypoxia. Pupillary enlargement seen during dying more
or less coincides with, but need not be due to, cessation of
cerebral circulation. Clearly, explanations of pupillary
signs in respiratory diseases need revision.
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Summary Intravenous 
infusion of 500 ml. 6%
polyvinylpyrrolidone (P.V.P. (Mw 40,000)
in isotonic saline solution over a 2-hour period significantly
diminished platelet adhesiveness in eight subjects from
27% before infusion to as low as 10% at the end of the
infusion. 5 hours after the end of the infusion, platelet
adhesiveness was still significantly reduced (16%). The
addition of P.V.P. to citrated blood in vitro significantly
decreased platelet adhesiveness. Both in vivo and in vitro,
the platelet-count was not significantly altered by P.V.P.
The in-vivo change in platelet adhesiveness is similar to
that reported by others with dextran-a plasma expander
that differs chemically from P.V.P.
Introduction
POLYVINYLPYRROLIDONE (P.v.P.) is a plasma-volume
expander (Gropper et al. 1952) which was developed
during the early part of the 1939-45 war by Hecht and
Weese (1943). Its haemodynamic effects, which result in
part from plasma expansion, have been well documented
(De Freitas et al. 1965). Of particular interest, however,
918
are the varied properties of P.V.P. which seemingly are not
related to plasma-volume expansion. P.v.p. can chemically
bind dyes, bilirubin, insulin, penicillin, and other drugs
(Gropper et al. 1952). Intravenous infusion of P.v.p.
strikingly diminishes serum-lipid concentrations in the
nephrotic syndrome (Allen et al. 1961) and in familial
hyperlipoproteinaemia (Sanbar et al. 1967). P.v.p. infusion
has been shown to increase the aggregation of erythrocytes
(Korth and Heinlein 1943) and their sedimentation-rate
(Guillot and Fiehrer 1948) but does not lengthen the
bleeding-time or clotting-time (Thrower and Campbell
1951). Finally, high concentrations of P.V.P. (about 40%)
have been shown to protect human erythrocytes effectively
during frozen storage in liquid nitrogen (Richards et al.
1964). At these concentrations, P.v.p. precipitates some
plasma-proteins (Burstein 1961) such as almost all of the
plasma-fibrinogen and antihasmophilic factor vm and
variable amounts of other coagulation factors (Perkins
et al. 1966).
We report here another effect of P.v.p.-namely, that it
can diminish platelet adhesiveness in human blood both
in vivo and in vitro. Our investigation was prompted by
reports that dextran, a chemically different plasma
expander, decreases platelet adhesiveness in man (Bennett
et al. 1966, Bygdeman et al. 1966, Cronberg et al. 1966).
Subjects and Methods
In-vivo infusions were carried out on two men and six
women who had fasted for 12-16 hours. They were all
clinically well at the time, but they had essential hyper-
cholesterolxmia. After a baseline blood-sample was obtained,
each was given a 2-hour intravenous infusion of 500 ml. 6%
P.v.p. in isotonic saline solution. Blood-samples were then
taken at the end of the infusion, and at 4 and 7 hours after the
start of the infusion.
In-vitro tests.-Blood-samples, 20 ml. each, were obtained
from thirteen healthy volunteers and transferred to plastic
beakers. Portions were then drawn into individual 5 ml.
siliconised syringes as follows:
(1) 5-0 ml. blood was used as such with nothing added.
(2) 4-5 ml. blood, plus 0-5 ml. isotonic saline solution.
(3) 4-5 ml. blood, plus 0-5 ml. 6% P.v.p. in isotonic saline
solution.
(4) 4-5 ml. blood, plus 0-5 ml. isotonic saline solution.
The amount of P.v.p. selected was comparable to the amount
administered intravenously. Blood was kept at room-tempera-
ture while platelet adhesiveness was being measured succes-
sively in the order indicated.
Technique.-All blood-samples were initially collected in
siliconised glass syringes containing 3-8% sodium citrate (1
part citrate to 9 parts blood). Platelet adhesiveness to glass
beads was measured according to the technique of Hellem
(1960); the platelets were counted according to the method of
Brecher and Cronkite (1950).
Results
Intravenous infusion of 500 ml. 6% P.V.P. over a 2-hour
period decreased platelet adhesiveness in six of the eight
subjects (table i). In the two unaffected subjects, the
percentage of platelet adhesiveness was remarkably low
before the infusion. The mean percentage of platelet
adhesiveness was lowest at the end of the infusion and was
still significantly reduced 5 hours later. Mean (&plusmn; S.E.M.)
platelet-counts did not change significantly throughout the
procedure-261,000 (&plusmn; 28,000) before infusion, 234,500
(&plusmn; 23,900) at 2 hours, 242,000 (&plusmn; 25,500) at 4 hours, and
230,800 (  18,600) at 7 hours after the infusion was begun.
Table 11 shows that addition of 0-5 ml. isotonic saline
solution to 4-5 ml. blood (columns 3 and 5) had no influence
TABLE I-IN-VIVO INFUSION OF 500 ML. 6% P.V.P.
TABLE II-IN-VITRO EFFECT OF P.V.P. ON PLATELET ADHESIVENESS
on platelet adhesiveness of citrated whole blood (column 2),
On the other hand, the addition of 0-5 ml. 6% P.V.P. in
isotonic saline solution (column 4) decreased platelet
adhesiveness impressively. Mean (rb S.E.M.) platelet-
counts were not significantly different in the four sub-
groups-192,400 (&plusmn; 12,600), 181,100 (&plusmn; 14,300),165,700
(&plusmn; 12,300), and 175,500 (&plusmn; 12,300) beginning with
citrated blood only, then with saline solution, P.v.p., and
finally saline solution again.
Discussion
Our findings show that P.v.p. can substantially reduce
platelet adhesiveness in human blood both in vivo and
in vitro. This effect has not been previously reported,
though the chemically different plasma expander, dextran,
has been shown to influence platelet adhesiveness
(Bygdeman et al. 1966, Bennett et al. 1966). The effects
of these two plasma expanders on platelet adhesiveness,
however, are somewhat different. P.V.P. decreases plate-
let adhesiveness both in vivo and in vitro, whereas
dextran has not been shown to produce this effect in vitro
(Bygdeman and Eliasson 1966). P.V.P. exerts its maximum
effect on platelet adhesiveness at the end of the infusion of
the drug, whereas the maximum effect of dextran on
platelet adhesiveness does not coincide with its peak
concentration in the blood but is delayed for several hours
(Bennett et al. 1966, Cronberg et al. 1966).
How P.V.P. reduces platelet adhesiveness is not clear
from our investigation. The reduction is apparently not
secondary to changes in platelet-counts. Nor is it likely to
be related to changes in red-cell concentration (Hellem
1960), since the reduction in adhesiveness after P.v.p.
infusion is greater than would be expected from changes
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in haematocrit (Salzman and Neri 1966) and (more
importantly), because we found that dilution with equal
volumes of saline solution alone " in vitro " had no effect
at all. In view of the decrease in platelet adhesiveness by
P.v.P. both in vivo and in vitro, the most plausible
explanation is that P.v.p. " coats 
" the blood-platelets,
foreign surfaces, or erythrocytes, thereby preventing
adhesion of platelets to the foreign surface as well as
trauma to the erythrocytes and the consequent release of
adenosine diphosphate. Nevertheless, regardless of the
exact way in which P.v.p. decreases platelet adhesiveness,
the clinical potential of such an agent in the prevention of
thrombus formation or propagation is important. And, as
in the case of dextran (Bennett et al. 1966), the prophy-
lactic and therapeutic value of the possible antithrombotic
properties of P.v.p. should be fully investigated.
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Summary 
Two cases of hepatitis clinically and
biologically resembling acute viral hepatitis
are reported. In both, Toxoplasma gondii could be
demonstrated in the liver, together with a significant, rise
in antitoxoplasmic antibodies. The two cases had pro-
longed prodromal stages with lymphadenopathy, anorexia,
and fatigue before the onset of jaundice. It could be that
more cases of so-called viral hepatitis are caused by
T. gondii.
Introduction
SEROLOGICAL evidence indicates that about 20% of the
adult population have been infected at one time or another
with Toxoplasma gondii (Buhler 1963, Hurwitz 1965).
Infection after infancy usually passes unrecognised.
Sometimes it may cause chorioretinitis or lymphadeno-
pathy ; " glandular fever " unaccompanied by a Paul-
Bunnel reaction can be due to toxoplasmosis. Rare
manifestations are encephalitis, a severe and often fatal
typhus-like disease, and myocarditis (The Lancet 1959).
Liver involvement has been reported in patients with
generalised disease due to toxoplasma (Theologides and
Kennedy 1966). A chronic kind of hepatitis due to toxo-
plasmosis with slight elevation of serum-bilirubin has
been reported by Kabelitz (1959) who based his conclu-
sions on serological evidence. We describe here two cases
of acute hepatitis-in both, T. gondii was demonstrated in
the l ver.
Methods
Serological tests for toxoplasmosis were done with four
different techniques: the dye test (Sabin and Feldman 1948),
the indirect hasmagglutination reaction (I.H.R.; Jacobs and
Lunde 1957), the slide flocculation test (Engelbrecht .1965), and
a complement-fixation (c.F.) test using 1.5 units of complement
and the formalised insoluble residue of repeatedly frozen and
thawed, water-extracted toxoplasma as an antigen. T. gondii
was demonstrated in liver-biopsy specimens by immuno-
fluorescence : the tissues were fixed in acetone for 24 hours,
passed through benzene, and imbedded in paraffin wax at
50-55&deg;C. Sections were cut and, after paraffin wax had been
removed in benzene for 10 minutes, they were rinsed once in
acetone. Control slides of toxoplasmic mouse exudate were
treated in the same way. Of two successive sections and two
control slides one was treated with a known normal human
serum while the other one was treated with a human serum of
high dye-test titre (inhibitory serum), both sera being diluted
to 1/5 with phosphate-buffered saline solution pH 7,2.’ Slides
were incubated for 40 minutes at 37&deg;C and then rinsed with the
buffered saline solution. Subsequently, they were incubated
with a dilution of human serum which had a high dye-test titre,
conjugated with fluorescein isothiocyanate. After washing
several times in phosphate-buffered saline solution, the sections
were examined under the ultraviolet microscope. Of the control
slides, the one which was pretreated with normal serum showed
brilliant staining of the toxoplasma; the control slide with
inhibitory serum only showed faint fluorescence. The first of
the liver sections showed fluorescent particles morphologically
indistinguishable from T. gondii, while on the other section the
particles were seen at the same sites with only faint staining.
Case-reports
FIRST CASE
A 61-year-old housewife was admitted with jaundice on
Dec. 6, 1966. 3 months before admission, she had had an acute
febrile episode of 1 week’s duration, followed by asthenia,
fatigue, and subfebrile temperatures. Clinical examination
2 months before admission revealed two pea-sized mobile
anterior neck lymph-nodes. I.H.R. for toxoplasmosis showed
a titre of 1/160. 1 month’s treatment with sulphadimethoxine
and spiramycin had no effect. On Dec. 2, after a few days of
nausea, mild pruritus, dark urine, and light-coloured stools,
slight jaundice developed, and the patient was referred to
hospital. Past history revealed nothing relevant except hiatal
hernia. Blood had been taken several times during the 3
preceding months; otherwise there was no history of exposure
to hepatitis, hepatotoxic agents, or domestic pets. Physical
examination showed a moderately obese icteric woman who had
lately lost 4 kg. (8-8 lb.) of weight; liver tender and palpable
8 cm. below costal margin; a soft spleen 3 cm. below left costal
margin. Laboratory data are shown in the table. Peripheral
white-blood-cell count was 7200 with 27% polymorphnuclear
cells, 12-5% band forms, 0-5% eosinophils, 0-5% basophils,
14-5% monocytes, 43-5% lymphocytes with viral cytoplasm,
and 1-5% plasmocytes. The increase in mononuclear cells
persisted throughout the course of the disease. c.F. tests for
